title: Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis.
abstract: OBJECTIVE
  We evaluated the clinical pharmacokinetics of a sustained-release preparation of disopyramide phosphate (DSR) and its effects on supraventricular arrhythmias in hemodialysis patients.
  
  
  METHODS
  Eight hemodialysis patients with either paroxysmal supraventricular tachycardia (PSVT) or PSVT plus paroxysmal atrial fibrillation (Paf) were given 150 mg of DSR 2 h before each hemodialysis. The frequency of PSVT, the duration of Paf before and 2 weeks after starting DSR and the blood concentration of the drug were evaluated.
  
  
  RESULTS
  There was no significant difference between serum levels of DSR before and after hemodialysis. The frequency of PSVT and the duration of Paf were significantly reduced by the therapy. Side effects and electrocardiographic abnormalities did not appear during the period.
  
  
  CONCLUSIONS
  We conclude that hemodialysis does not remove DSR, and that a single dose of 150 mg of DSR given 2 h before hemodialysis is safe and sufficient to reduce the incidence of supraventricular arrhythmias.
authors.affiliation: Third Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Gunma, Japan. t-kaji@tohgoku.or.jp
authors.forename: T
authors.initials: T
authors.lastname: Kaji
authors.forename: Y
authors.initials: Y
authors.lastname: Nojima
authors.forename: H
authors.initials: H
authors.lastname: Arisaka
authors.forename: T
authors.initials: T
authors.lastname: Naruse
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000517:prevention & control; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D004206:Disopyramide / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013617:Tachycardia, Supraventricular / Q000188:drug therapy / Q000517:prevention & control; D014555:Urination Disorders; D014987:Xerostomia
chemical_list: D000889:Anti-Arrhythmia Agents; D003692:Delayed-Action Preparations; D004206:Disopyramide